Sangamo Therapeutics analyst ratings
Sangamo Therapeutics analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 06/13/2022 | 48.15% | Wedbush | → $5 | Assumes | → Neutral |
| 04/05/2022 | 462.96% | Truist Securities | $23 → $19 | Maintains | Buy |
| 05/04/2021 | 551.85% | RBC Capital | → $22 | Initiates Coverage On | → Outperform |
| 01/06/2021 | 374.07% | Stifel | → $16 | Initiates Coverage On | → Hold |
| 12/16/2020 | 640.74% | HC Wainwright & Co. | → $25 | Assumes | → Buy |
| 09/08/2020 | 492.59% | B of A Securities | → $20 | Reinstates | → Buy |
| 07/07/2020 | 551.85% | SunTrust Robinson Humphrey | → $22 | Initiates Coverage On | → Buy |
| 06/22/2020 | 314.81% | HC Wainwright & Co. | $16 → $14 | Maintains | Buy |
| 11/14/2018 | 225.93% | JP Morgan | $35 → $11 | Maintains | Neutral |
| 11/14/2018 | 225.93% | JP Morgan | $35 → $11 | Downgrades | Overweight → Neutral |
| 11/09/2018 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 06/20/2018 | 611.11% | B of A Securities | → $24 | Initiates Coverage On | → Buy |
| 11/22/2017 | 492.59% | Barclays | → $20 | Initiates Coverage On | → Overweight |
| 11/15/2017 | — | Piper Sandler | Upgrades | Neutral → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 06/13/2022 | 48.15% | 韋德布什 | → $5 | 假設 | →中性 |
| 04/05/2022 | 462.96% | Truist證券 | $23 → $19 | 維護 | 買 |
| 05/04/2021 | 551.85% | 加拿大皇家銀行資本 | → $22 | 開始承保 | →跑贏大盤 |
| 01/06/2021 | 374.07% | Stifel | → $16 | 開始承保 | →保留 |
| 12/16/2020 | 640.74% | HC Wainwright公司 | → $25 | 假設 | →購買 |
| 09/08/2020 | 492.59% | B of A證券 | → $20 | 恢復 | →購買 |
| 07/07/2020 | 551.85% | SunTrust Robinson Humphrey | → $22 | 開始承保 | →購買 |
| 06/22/2020 | 314.81% | HC Wainwright公司 | $16 → $14 | 維護 | 買 |
| 11/14/2018 | 225.93% | 摩根大通 | $35 → $11 | 維護 | 中性 |
| 11/14/2018 | 225.93% | 摩根大通 | $35 → $11 | 評級下調 | 超重→中性 |
| 11/09/2018 | — | 古根海姆 | 評級下調 | 購買→中性 | |
| 06/20/2018 | 611.11% | B of A證券 | → $24 | 開始承保 | →購買 |
| 11/22/2017 | 492.59% | 巴克萊 | → $20 | 開始承保 | →超重 |
| 11/15/2017 | — | 派珀·桑德勒 | 升級 | 中性→超重 |
Sangamo Therapeutics Questions & Answers
Sangamo治療公司問答
The latest price target for Sangamo Therapeutics (NASDAQ: SGMO) was reported by Wedbush on June 13, 2022. The analyst firm set a price target for $5.00 expecting SGMO to rise to within 12 months (a possible 48.15% upside). 2 analyst firms have reported ratings in the last year.
韋德布什於2022年6月13日報道了Sangamo治療公司(納斯達克：SGMO)的最新目標價。這家分析公司將目標價定為5.00美元，預計SGMO將在12個月內上漲(可能上漲48.15%)。去年有兩家分析公司公佈了評級。
The latest analyst rating for Sangamo Therapeutics (NASDAQ: SGMO) was provided by Wedbush, and Sangamo Therapeutics their neutral rating.
韋德布什公司對Sangamo治療公司(納斯達克代碼：SGMO)的最新分析師評級，Sangamo治療公司的中性評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sangamo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sangamo Therapeutics was filed on June 13, 2022 so you should expect the next rating to be made available sometime around June 13, 2023.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閲公共財務報表，與Sangamo治療公司的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Sangamo治療公司的上一次評級是在2022年6月13日提交的，所以你應該預計下一次評級將在2023年6月13日左右的某個時候提供。
While ratings are subjective and will change, the latest Sangamo Therapeutics (SGMO) rating was a with a price target of $0.00 to $5.00. The current price Sangamo Therapeutics (SGMO) is trading at is $3.38, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Sangamo治療(SGMO)評級為A，目標價在0.00美元至5.00美元之間。Sangamo治療公司(SGMO)目前的交易價格為3.38美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。